94 related articles for article (PubMed ID: 1987897)
1. [Tumor markers--personal experience. Ha-ras P21 in neuroblastoma: a new marker associating to patient's prognosis].
Tanaka T
Gan To Kagaku Ryoho; 1991 Jan; 18(1):143-50. PubMed ID: 1987897
[TBL] [Abstract][Full Text] [Related]
2. Ha-ras p21 in neuroblastoma: a new marker in prediction of patient outcome.
Tanaka T
Prog Clin Biol Res; 1994; 385():275-80. PubMed ID: 7972221
[No Abstract] [Full Text] [Related]
3. Prognostic prediction in neuroblastomas: clinical significance of combined analysis for Ha-ras p21 expression and N-myc gene amplification.
Tanaka T; Seeger RC; Tanabe M; Hiyama E; Shimoda H; Ida N
Cancer Detect Prev; 1994; 18(4):283-9. PubMed ID: 7982238
[TBL] [Abstract][Full Text] [Related]
4. Expression of Ha-ras oncogene products in human neuroblastomas and the significant correlation with a patient's prognosis.
Tanaka T; Slamon DJ; Shimoda H; Waki C; Kawaguchi Y; Tanaka Y; Ida N
Cancer Res; 1988 Feb; 48(4):1030-4. PubMed ID: 3276397
[TBL] [Abstract][Full Text] [Related]
5. Expressions of N-myc and ras oncogene products in neuroblastoma and their correlations with prognosis.
Nakada K; Fujioka T; Kitagawa H; Takakuwa T; Yamate N
Jpn J Clin Oncol; 1993 Jun; 23(3):149-55. PubMed ID: 8350488
[TBL] [Abstract][Full Text] [Related]
6. A significant association of Ha-ras p21 in neuroblastoma cells with patient prognosis. A retrospective study of 103 cases.
Tanaka T; Slamon DJ; Shimada H; Shimoda H; Fujisawa T; Ida N; Seeger RC
Cancer; 1991 Sep; 68(6):1296-302. PubMed ID: 1873783
[TBL] [Abstract][Full Text] [Related]
7. Ha-ras oncogene product in human oral squamous cell carcinoma.
Oku N; Shimada K; Itoh H
Kobe J Med Sci; 1989 Dec; 35(5-6):277-86. PubMed ID: 2699627
[TBL] [Abstract][Full Text] [Related]
8. Multifocal neuroblastoma: biologic behavior and surgical aspects.
Hiyama E; Yokoyama T; Hiyama K; Yamaoka H; Matsuura Y; Nishimura Si; Ueda K
Cancer; 2000 Apr; 88(8):1955-63. PubMed ID: 10760774
[TBL] [Abstract][Full Text] [Related]
9. Expression of N-myc and c-src protooncogenes correlating to the undifferentiated phenotype and prognosis of primary neuroblastomas.
Matsunaga T; Takahashi H; Ohnuma N; Tanabe M; Yoshida H; Iwai J; Shirasawa H; Simizu B
Cancer Res; 1991 Jun; 51(12):3148-52. PubMed ID: 2039993
[TBL] [Abstract][Full Text] [Related]
10. N-myc amplification and cell proliferation rate in human neuroblastoma.
Pession A; Trerè D; Perri P; Rondelli R; Montanaro L; Mantovani W; Derenzini M; Paolucci G
J Pathol; 1997 Nov; 183(3):339-44. PubMed ID: 9422991
[TBL] [Abstract][Full Text] [Related]
11. Expression of the apoptosis-suppressing protein bcl-2, in neuroblastoma is associated with unfavorable histology and N-myc amplification.
Castle VP; Heidelberger KP; Bromberg J; Ou X; Dole M; Nuñez G
Am J Pathol; 1993 Dec; 143(6):1543-50. PubMed ID: 8256847
[TBL] [Abstract][Full Text] [Related]
12. [Amplification of the N-myc cellular oncogene in neuroblastoma. Relation to other tumor markers].
Verdona G; Garaventa A; Coviello DA; Cornaglia-Ferraris P; Tonini GP
Boll Ist Sieroter Milan; 1986; 65(4):304-8. PubMed ID: 3790277
[TBL] [Abstract][Full Text] [Related]
13. Expression of type I interferon receptor and its relation with other prognostic factors in human neuroblastoma.
Mejía C; Navarro S; Colamonici OR; Pellín A; Castel V; Llombart-Bosch A
Oncol Rep; 1999; 6(1):149-53. PubMed ID: 9864419
[TBL] [Abstract][Full Text] [Related]
14. Proliferation marker KI-S5 discriminates between favorable and adverse prognosis in advanced stages of neuroblastoma with and without MYCN amplification.
Krams M; Hero B; Berthold F; Parwaresch R; Harms D; Rudolph P
Cancer; 2002 Feb; 94(3):854-61. PubMed ID: 11857322
[TBL] [Abstract][Full Text] [Related]
15. Neuroblastoma and the clinical significance of N-myc oncogene amplification.
Phillips WS; Stafford PW; Duvol-Arnold B; Ghosh BC
Surg Gynecol Obstet; 1991 Jan; 172(1):73-80. PubMed ID: 1985349
[No Abstract] [Full Text] [Related]
16. N-myc gene amplification in neuroblastoma determined by the polymerase chain reaction.
Norris MD; Haber M; Gilbert J; Kavallaris M; Marshall GM; Stewart BW
Prog Clin Biol Res; 1994; 385():27-33. PubMed ID: 7972220
[No Abstract] [Full Text] [Related]
17. Cross-study analysis of gene expression data for intermediate neuroblastoma identifies two biological subtypes.
Warnat P; Oberthuer A; Fischer M; Westermann F; Eils R; Brors B
BMC Cancer; 2007 May; 7():89. PubMed ID: 17531100
[TBL] [Abstract][Full Text] [Related]
18. Induction of N-myc in neuroblastoma by autocrine IGF-II depends on farnesylated Ras. Application of farnesyltransferase inhibitors.
Wittrock J; Schweizer P; Girgert R
Anticancer Res; 2002; 22(6C):4205-9. PubMed ID: 12553057
[TBL] [Abstract][Full Text] [Related]
19. Overexpression and amplification of c-myc and c-Ha-ras oncogenes in pleomorphic salivary adenoma.
Xue H; Situ ZQ; Wang CJ; Wu JZ
Chin Med J (Engl); 1993 Jan; 106(1):22-5. PubMed ID: 8389270
[TBL] [Abstract][Full Text] [Related]
20. [c-myc and c-Ha-ras proto-oncogenes in cervical cancer: prognostic value].
Riou G; Sheng ZM; Zhou D; Lusinchi A; Le Doussal V; Barrois M
Bull Cancer; 1990; 77(4):341-7. PubMed ID: 2191730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
